Cummings, K. Michael
Talbot, Vincent
Roberson, Avery
Bliss, Asia A.
Likins, Emily
Brownstein, Naomi C.
Stansell, Stephanie
Adams-Ludd, Demetress
Harris, Bridget
Louder, David
McCutcheon, Edward
Zebian, Rami
Rojewski, Alana M.
Toll, Benjamin A.
Article History
Received: 1 September 2023
Accepted: 13 June 2024
First Online: 17 June 2024
Declarations
:
: This research study was reviewed and approved with respect to the study of human subjects by the Medical University of South Carolina’s Institutional Review Board-I, Study Protocol #107000, under expedited review procedures. A HIPAA Waiver of Authorization for Research was requested and subsequently approved due to the study involving no more than minimal risk to the subject, thus satisfying Privacy rule 45 CFR 46.110 and 21 CFR 56.10. We requested a waiver of consent due to the high volume of patients who reside geographically across the state of South Carolina. Obtaining written authorization for home, often-ill discharged patients would increase the loss of confidentiality and could not practically be conducted. Consent occurred in two ways: 1) Limited PHI Data request; and 2) Verbal consent for the 6-week follow up survey. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: VT is employed by TelASK the vendor hired by MUSC to operate the Quit Plan Manager™ system used for patient tracking. KMC and BAT both have received payments as expert witnesses in litigation filed against the tobacco industry. All other authors have no conflicts to report.